Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
32
ANL Quote, Financials, Valuation and Earnings
Last price:
$1.55
Seasonality move
:
-3.96%
Day range:
$1.46 - $1.55
52-week range:
$0.88 - $2.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.24x
Volume:
22.9K
Avg. volume:
24.9K
1-year change:
-33.57%
Market cap:
$57.2M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ANL
Adlai Nortye Ltd.
|
-- | -$1.31 | -- | -33.06% | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.18% | -46.43% | $49.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ANL
Adlai Nortye Ltd.
|
$1.55 | -- | $57.2M | -- | $0.00 | 0% | -- |
|
ADAG
Adagene, Inc.
|
$1.85 | $9.22 | $87.2M | -- | $0.00 | 0% | 832.60x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.78 | $4.00 | $16.1M | -- | $0.00 | 0% | 0.46x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.31 | -- | $4.3M | -- | $0.00 | 0% | 1.06x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$18.58 | $49.17 | $2.1B | -- | $0.00 | 0% | 4.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ANL
Adlai Nortye Ltd.
|
-- | -0.956 | -- | -- |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ANL
Adlai Nortye Ltd.
|
-- | -- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Adlai Nortye Ltd. vs. Competitors
-
Which has Higher Returns ANL or ADAG?
Adagene, Inc. has a net margin of -- compared to Adlai Nortye Ltd.'s net margin of --. Adlai Nortye Ltd.'s return on equity of -- beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital ANLAdlai Nortye Ltd.-- -- -- ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About ANL or ADAG?
Adlai Nortye Ltd. has a consensus price target of --, signalling upside risk potential of 492.11%. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 398.61%. Given that Adlai Nortye Ltd. has higher upside potential than Adagene, Inc., analysts believe Adlai Nortye Ltd. is more attractive than Adagene, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANLAdlai Nortye Ltd.0 1 0 ADAGAdagene, Inc.6 2 0 -
Is ANL or ADAG More Risky?
Adlai Nortye Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ANL or ADAG?
Adlai Nortye Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adlai Nortye Ltd. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANL or ADAG?
Adlai Nortye Ltd. quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. Adlai Nortye Ltd.'s net income of -- is lower than Adagene, Inc.'s net income of --. Notably, Adlai Nortye Ltd.'s price-to-earnings ratio is -- while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adlai Nortye Ltd. is -- versus 832.60x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANLAdlai Nortye Ltd.-- -- -- -- ADAGAdagene, Inc.832.60x -- -- --
-
Which has Higher Returns ANL or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to Adlai Nortye Ltd.'s net margin of -353.92%. Adlai Nortye Ltd.'s return on equity of -- beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital ANLAdlai Nortye Ltd.-- -- -- CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About ANL or CASI?
Adlai Nortye Ltd. has a consensus price target of --, signalling upside risk potential of 492.11%. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 431.07%. Given that Adlai Nortye Ltd. has higher upside potential than CASI Pharmaceuticals, Inc., analysts believe Adlai Nortye Ltd. is more attractive than CASI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANLAdlai Nortye Ltd.0 1 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is ANL or CASI More Risky?
Adlai Nortye Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock ANL or CASI?
Adlai Nortye Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adlai Nortye Ltd. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANL or CASI?
Adlai Nortye Ltd. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Adlai Nortye Ltd.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Adlai Nortye Ltd.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adlai Nortye Ltd. is -- versus 0.46x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANLAdlai Nortye Ltd.-- -- -- -- CASICASI Pharmaceuticals, Inc.0.46x -- $3.1M -$10.9M
-
Which has Higher Returns ANL or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to Adlai Nortye Ltd.'s net margin of -86.16%. Adlai Nortye Ltd.'s return on equity of -- beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital ANLAdlai Nortye Ltd.-- -- -- CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About ANL or CPHI?
Adlai Nortye Ltd. has a consensus price target of --, signalling upside risk potential of 492.11%. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Adlai Nortye Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe Adlai Nortye Ltd. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANLAdlai Nortye Ltd.0 1 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is ANL or CPHI More Risky?
Adlai Nortye Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock ANL or CPHI?
Adlai Nortye Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adlai Nortye Ltd. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANL or CPHI?
Adlai Nortye Ltd. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Adlai Nortye Ltd.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Adlai Nortye Ltd.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adlai Nortye Ltd. is -- versus 1.06x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANLAdlai Nortye Ltd.-- -- -- -- CPHIChina Pharma Holdings, Inc.1.06x -- $756.2K -$651.5K
-
Which has Higher Returns ANL or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to Adlai Nortye Ltd.'s net margin of --. Adlai Nortye Ltd.'s return on equity of -- beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital ANLAdlai Nortye Ltd.-- -- -- SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About ANL or SVA?
Adlai Nortye Ltd. has a consensus price target of --, signalling upside risk potential of 492.11%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Adlai Nortye Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Adlai Nortye Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ANLAdlai Nortye Ltd.0 1 0 SVASinovac Biotech Ltd.0 0 0 -
Is ANL or SVA More Risky?
Adlai Nortye Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock ANL or SVA?
Adlai Nortye Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Adlai Nortye Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios ANL or SVA?
Adlai Nortye Ltd. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Adlai Nortye Ltd.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Adlai Nortye Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adlai Nortye Ltd. is -- versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANLAdlai Nortye Ltd.-- -- -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns ANL or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Adlai Nortye Ltd.'s net margin of -30.98%. Adlai Nortye Ltd.'s return on equity of -- beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital ANLAdlai Nortye Ltd.-- -- -- ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About ANL or ZLAB?
Adlai Nortye Ltd. has a consensus price target of --, signalling upside risk potential of 492.11%. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 164.64%. Given that Adlai Nortye Ltd. has higher upside potential than Zai Lab Ltd., analysts believe Adlai Nortye Ltd. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ANLAdlai Nortye Ltd.0 1 0 ZLABZai Lab Ltd.8 1 0 -
Is ANL or ZLAB More Risky?
Adlai Nortye Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock ANL or ZLAB?
Adlai Nortye Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adlai Nortye Ltd. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANL or ZLAB?
Adlai Nortye Ltd. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Adlai Nortye Ltd.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Adlai Nortye Ltd.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adlai Nortye Ltd. is -- versus 4.51x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANLAdlai Nortye Ltd.-- -- -- -- ZLABZai Lab Ltd.4.51x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
